Pilot Trial of Short Course Radiotherapy for Primary or Secondary CNS Malignancies
Summary
This is a single arm prospective pilot trial determining the safety of short-course radiation therapy in pediatric patients with incurable central nervous system malignancies.
Detailed description
Participants will receive a shorter course of radiation therapy across 5 days (20 Gray in 5 fractions) in contrast to the standard treatment of two weeks or more of daily treatments (up to 3 Gray per day). This research study is being conducted to see if delivering a shorter course of radiation therapy is safe and helps quality of life so that it may reduce the required duration of palliative treatment.
Arms & interventions
- RadiationShort Course Radiotherapy
Participants will receive a shorter course of radiation therapy across 5 days (20 Gray in 5 fractions).
Outcome measures
Primary
Safety of Short Course Radiotherapy
The ability to complete short-course radiotherapy without grade 3 or higher adverse events (AE) that are possibly, probably, or definitely related to radiotherapy during the study period Any individual grade 3 or higher AE that is reported during the study period and deemed possibly, probably, or definitely related to short course radiotherapy will automatically prevent the study from meeting its primary endpoint.
Time frame: 1 year
Secondary
Pediatric Quality of Life after Short Course Radiotherapy
Time frame: 1 year
Adolescent Quality of Life after Short Course Radiotherapy
Time frame: 1 year
Overall Survival after Short Course Radiotherapy
Time frame: 1 year
Steroid Usage
Time frame: 1 year
Eligibility criteria
Study locations (1)
University of Pennsylvania
Philadelphia, Pennsylvania, 19104